CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. As of August 18, 2025, CARGO Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Frequently asked questions
What sector does CARGO Therapeutics, Inc. Common Stock (CRGX) operate in?
CARGO Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CARGO Therapeutics, Inc. Common Stock (CRGX) current stock price?
As of the latest data, CARGO Therapeutics, Inc. Common Stock stock price is $4.47, with a previous close of $4.47.
What is CARGO Therapeutics, Inc. Common Stock (CRGX) current market capitalization?
CARGO Therapeutics, Inc. Common Stock market cap is approximately 216.19 million.
What is CARGO Therapeutics, Inc. Common Stock (CRGX) Earnings Per Share (EPS)?
The trailing EPS is -$4.62, and the forward EPS is -$3.55.
Does CARGO Therapeutics, Inc. Common Stock (CRGX) pay dividends?
No. CARGO Therapeutics, Inc. Common Stock does not pay a dividend.
What is CARGO Therapeutics, Inc. Common Stock (CRGX) beta (volatility) score?
CARGO Therapeutics, Inc. Common Stock has a beta of -0.054, indicating lower volatility than the overall market.
